The angiotensinogen AGT p.M235T gene polymorphism may be responsible for the development of severe anaphylactic reactions to insect venom allergens

International Archives of Allergy and Immunology

Volumn 153, Issue 2, 2010, Pages 166-172

  Niedoszytko, Marek ^a   Ratajska, Magdalena ^a   Chełmińska, Marta ^a   Makowiecki, Michał ^a   Malek, Ewelina ^a   Siemińska, Alicja ^a   Limon, Janusz ^a   Jassem, Ewa ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Genetics; I D ACE; Insect venom allergy; M235T AGT

Indexed keywords

ANGIOTENSIN I; ANGIOTENSINOGEN; INSECT VENOM; ALLERGEN; ARTHROPOD VENOM; BEE VENOM; DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT; AGED; ANAPHYLAXIS; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; IMMUNOTHERAPY; INSECT ALLERGY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; ADOLESCENT; ANIMAL; BLOOD; GENETICS; HYMENOPTERA; IMMUNOLOGY; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; ALLERGENS; ANAPHYLAXIS; ANGIOTENSIN I; ANGIOTENSINOGEN; ANIMALS; ARTHROPOD VENOMS; BEE VENOMS; FEMALE; HUMANS; HYMENOPTERA; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC;

EID: 77951072563     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000312634     Document Type: Article

References (32)

1. Bilo BM, Rueff F, Mosbech H, Bonifazi F, Oude-Elberink JN: Diagnosis of Hymenoptera venom allergy. Allergy 2005; 60: 1339-1349.
2. Bonifazi F, Jutel M, Bilo BM, Birnbaum J, Muller U: Prevention and treatment of Hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005; 60: 1459-1470.
3. Finegold I: Issues in stinging insect allergy immunotherapy: a review. Curr Opin Allergy Clin Immunol 2008; 8: 343-347.
4. Lieberman P: Epidemiology of anaphylaxis. Curr Opin Allergy Clin Immunol 2008; 8: 316-320.
5. Mueller HL: Diagnosis and treatment of insect sensitivity. J Asthma Res 1966; 3: 331-333.
6. Hermann K, Ring J: The renin-angiotensin system in patients with repeated anaphylactic reactions during Hymenoptera venom hyposensitization and sting challenge. Int Arch Allergy Immunol 1997; 112: 251-256.
7. Hermann K, Ring J: Histamine, tryptase, norepinephrine, angiotensinogen, angiotensin-converting enzyme, angiotensin I and II in plasma of patients with Hymenoptera venom anaphylaxis. Int Arch Allergy Immunol 1994; 104: 379-384.
8. Hermann K, Ring J: Association between the renin angiotensin system and anaphylaxis. Adv Exp Med Biol 1995; 377: 299-309.
9. Hermann K, Ring J: Human leukocytes contain angiotensin I, angiotensin II and angiotensin metabolites. Int Arch Allergy Immunol 1994; 103: 152-159.
10. Hermann K, Ring J: The renin angiotensin system and Hymenoptera venom anaphylaxis. Clin Exp Allergy 1993; 23: 762-769.
11. Hermann K, Donhauser S, Ring J: Angiotensin in human leukocytes of patients with insect venom anaphylaxis and healthy volunteers. Int Arch Allergy Immunol 1995; 107: 385-386.
12. Rush JW, Aultman CD: Vascular biology of angiotensin and the impact of physical activity. Appl Physiol Nutr Metab 2008; 33: 162-172.
13. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346.
14. Azizi M, Hallouin MC, Jeunemaitre X, Guyene T, Menard J: Influence of the M235T polymorphism of human angiotensinogen (AGT) on plasma AGT and renin concentrations after ethinylestradiol administration. J Clin Endocr Metab 2000; 85: 4331-4337.
15. Mondorf UF, Russ A, Wiesemann A, Herrero M, Oremek G, Lenz T: Contribution of angiotensin I converting enzyme gene polymorphism and angiotensinogen gene polymorphism to blood pressure regulation in essential hypertension. Am J Hypertens 1998; 11: 174-183.
16. Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, LaMotte F, Buring J, Hennekens CH: A prospective evaluation of an angiotensin- converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 1995; 332: 706-711.
17. Prasad A, Narayanan S, Waclawiw MA, Epstein N, Quyyumi AA: The insertion/deletion polymorphism of the angiotensin-converting enzyme gene determines coronary vascular tone and nitric oxide activity. J Am Coll Cardiol 2000; 36: 1579-1586.
18. Villard E, Tiret L, Visvikis S, Rakotovao R, Cambien F, Soubrier F: Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis. Am J Hum Genet 1996; 58: 1268-1278.
19. Benessiano J, Crestani B, Mestari F, Klouche W, Neukirch F, Hacein-Bey S, Durand G, Aubier M: High frequency of a deletion polymorphism of the angiotensin-converting enzyme gene in asthma. J Allergy Clin Immunol 1997; 99: 53-57.
20. Holla L, Vask A, Znojil V, Sisková L, Vácha J: Association of 3 gene polymorphisms with atopic diseases. J Allergy Clin Immunol 1999; 103: 702-708.
21. Kim JJ, Kim HJ, Lee IK, Chung HT, Lee JH: Association between polymorphisms of the angiotensin-converting enzyme and angiotensinogen genes and allergic rhinitis in a Korean population. Ann Otol Rhinol Laryngol 2004; 113: 297-302.
22. Lee YC, Cheon KT, Lee HB, Kim W, Rhee YK, Kim DS: Gene polymorphism of endothelial nitric oxide synthase and angiotensin-converting enzyme in patients with asthma. Allergy 2000; 55: 959-963.
23. Kim TH, Chang HS, Park SM, Nam BY, Park JS, Rhim T, Park HS, Kim MK, Choi IS, Cho SH, Chung IY, Park BL, Park CS, Shin HD: Association of angiotensin I-converting enzyme gene polymorphisms with aspirin intolerance in asthmatics. Clin Exp Allergy 2008; 38: 1727-1737.
24. Brasier AR, Ron D, Tate JE, Habener JF: A family of constitutive C/EBP-like DNA binding proteins attenuate the IL-1 alpha induced, NF kappa B mediated trans-activation of the angiotensinogen gene acutephase response element. EMBO J 1990; 9: 3933-3944.
25. Stumpf JL, Shehab N, Patel AC: Safety of angiotensin-converting enzyme inhibitors in patients with insect venom allergies. Ann Pharmacother 2006; 40: 699-703.
26. White KM, England RW: Safety of angiotensin-converting enzyme inhibitors while receiving venom immunotherapy. Ann Allergy Asthma Immunol 2008; 101: 426-430.
27. Lieberman P: Anaphylaxis. Med Clin North Am 2006; 90: 77-95.
28. Jutel M, Akdis M, Blaser K, Akdis CA: Mechanisms of allergen specific immunotherapy -T-cell tolerance and more. Allergy 2006; 61: 796-807.
29. Kawabata Y, Yang TS, Yokochi TT, Matsushita M, Fujita T, Shibazaki M, Noikura T, Endo TY, Takada H: Complement system is involved in anaphylactoid reaction induced by lipopolysaccharides in muramyldipeptide-treated mice. Shock 2000; 14: 572-577.
30. Volcheck G, Butterfield J, Yunginger J, Klee G: Elevated serum levels of calcitonin generelated peptide in Hymenoptera venom anaphylaxis. J Allergy Clin Immunol 1998; 102: 149-151.
31. Konno S, Hizawa N, Nishimura M, Huang SK: Osteopontin: a potential biomarker for successful bee venom immunotherapy and a potential molecule for inhibiting IgE-mediated allergic responses. Allergol Int 2006; 55: 355-359.
32. Lawley H, Hird H, Mallinder P: Detection of an activating c-kit mutation by real-time PCR in patients with anaphylaxis. Mutat Res 2005; 572: 1-13.